ABLYNX ANNOUNCES WARRANT EXERCISE

REGULATED INFORMATION

GHENT, Belgium, Oct. 21, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 5,200 common shares have been issued by the Company in exchange for €41,249 as the result of the exercise of warrants by some employees and consultants of the Company.

As a result of this transaction, Ablynx now has 54,517,624 shares outstanding.

The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights currently is 2,890,495 which equals the total number of voting rights that may result from the exercise of these warrants. Currently 1,000 convertible bonds are outstanding entitling the holders thereof to 7,733,952 shares of the Company in the aggregate, upon conversion of such convertible bonds.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Merck KGaA, Novartis and Taisho Pharmaceutical. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact Ablynx: Dr Edwin Moses CEO t:   +32 (0)9 262 00 07 m: +32 (0)473 39 50 68 e:  [email protected]

Marieke Vermeersch Associate Director Investor Relations t:   +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e:  [email protected] Follow us on Twitter @AblynxABLX

Ablynx media relations Instinctif Partners: Sue Charles, Daniel Gooch London office t:   +44 (0)20 7866 7905 e:  [email protected]

Belgium/Dutch and French language Jim Rusagara Brussels office t:   +32 (0)2 626 9500 e:  [email protected]

pdf format of the press release http://hugin.info/137912/R/1960169/714462.pdf

HUG#1960169

You May Also Be Interested In

• Homelessness and Drug Policy Expert Tom Wolf Joins Discovery Institute's Fix Homelessness Initiative
• Aedifica NV/SA – Extraordinary General Meeting of 12 June 2026: Aedifica shareholders approved the merger by absorption of Cofinimmo
• From Nokia to NeOnc: The Stocks Dominating Screens as Volume Spikes